Oncodrex Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$564K
- Investors
-
2
Oncodrex General Information
Description
Operator of a cancer diagnostics company designed to develop a colorectal cancer screening test. The company's technology is based on the discovery of two biomarkers that are present in high concentrations in the peripheral blood of cyclic redundancy check patients, enabling patients to avail of a cost-effective, highly sensitive, and reliable test for detecting colorectal cancer.
Contact Information
Website
www.oncodrex.comCorporate Office
- 158 Commerce Drive
- Winnipeg, Manitoba R3P 0Z6
- Canada
Corporate Office
- 158 Commerce Drive
- Winnipeg, Manitoba R3P 0Z6
- Canada
Oncodrex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 30-Jun-2019 | $564K | Completed | Clinical Trials - General | ||
| 2. Angel (individual) | 14-Feb-2018 | Completed | Clinical Trials - General | |||
| 1. Angel (individual) | 01-Aug-2017 | Completed | Clinical Trials - General |
Oncodrex Patents
Oncodrex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3023175-A1 | N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer | Pending | 03-May-2016 | ||
| EP-3452831-A1 | N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer | Active | 03-May-2016 | ||
| EP-3452831-A4 | N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer | Active | 03-May-2016 | ||
| EP-3452831-B1 | N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer | Active | 03-May-2016 | ||
| US-12024748-B2 | N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer | Active | 03-May-2016 | C12Q1/6883 |
Oncodrex Signals
Oncodrex Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovate Manitoba | Accelerator/Incubator | |||
| Valhalla Private Capital | Angel Group | Minority |
Oncodrex FAQs
-
When was Oncodrex founded?
Oncodrex was founded in 2014.
-
Where is Oncodrex headquartered?
Oncodrex is headquartered in Winnipeg, Canada.
-
What is the size of Oncodrex?
Oncodrex has 2 total employees.
-
What industry is Oncodrex in?
Oncodrex’s primary industry is Biotechnology.
-
Is Oncodrex a private or public company?
Oncodrex is a Private company.
-
What is Oncodrex’s current revenue?
The current revenue for Oncodrex is .
-
How much funding has Oncodrex raised over time?
Oncodrex has raised $25K.
-
Who are Oncodrex’s investors?
Innovate Manitoba and Valhalla Private Capital have invested in Oncodrex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process